Public-private partnerships shrank to 301 deals in 2013, down one-fifth from the year prior. Cancer again predominated (84 deals), with neurology (35 deals) and infectious disease (34 deals) second and third in the rankings (Fig. 1). Harvard University was the most active deal maker (Table 1), but both Johns Hopkins University and KU Leuven broke into the top 5 in 2013. AstraZeneca was the most active pharmaceutical firm (14 deals), whereas GlaxoSmithKline fell from its zenith of 14 deals in 2012 to just 9 last year (Fig. 2).
About this article
Cite this article
Huggett, B. Academic-industry partnerships 2013. Nat Biotechnol 32, 313 (2014). https://doi.org/10.1038/nbt.2861
This article is cited by
Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest
Clinical and Translational Medicine (2015)